Collect Product
Product Details
Synonyms
ERBB2, CD340, HER-2, neu, HER2, MLN19, NEU, NGL, TKR1
Source
Biotinylated Rat Her2 Protein, His,Avitag (HE2-R82E3) is expressed from human 293 cells (HEK293). It contains AA Thr 26 - Thr 656 (Accession # AAH61863.1).
Predicted N-terminus: Thr 26
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 73.3 kDa. The protein migrates as 80-100 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Labeling
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Protein Ratio
Passed as determined by the HABA assay / binding ELISA.
Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
SDS-PAGE
Biotinylated Rat Her2 Protein, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Biotinylated Rat Her2 Protein, His,Avitag (Cat. No. HE2-R82E3) is more than 90% and the molecular weight of this protein is around 70-100 kDa verified by SEC-MALS.
Report
User Reviews Publish Comment
Background Introduction
Aberrant amplification or overexpression of the HER2/neu proto-oncogene is a key oncogenic driver. In breast cancer, approximately 25-30% of patients exhibit HER2 overexpression, leading to a more aggressive disease phenotype with faster growth, increased metastasis, and often reduced chemotherapy sensitivity. This correlates with poorer prognosis and makes HER2 a critical prognostic, predictive biomarker, and a major therapeutic target.
Frontier Progress
Drug Development Progress- English Name：
Receptor protein-tyrosine kinase erbB-2
- Category：
- Listed Drugs Count：
47 Details
- Clinical Drugs Count：
238 Details
- Highest R&D Stage：
Approved
Contact Us
Drug Candidate Licensing
